Bowers P N, Fields J, Schwartz D, Rosenfeld L E, Nehgme R
Section of Pediatric Cardiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Pacing Clin Electrophysiol. 1998 Aug;21(8):1665-7. doi: 10.1111/j.1540-8159.1998.tb00257.x.
We report a case of pulmonary fibrosis in an infant receiving amiodarone for treatment of intractable atrioventricular reentrant tachycardia secondary to Wolff-Parkinson-White syndrome. At 9 months, a screening chest radiograph showed a diffuse interstitial infiltrate in an asymptomatic, thriving infant. Amiodarone was discontinued and the pulmonary fibrosis resolved gradually over 6 months. This case documents the first report of amiodarone induced pulmonary fibrosis in the pediatric age group. We speculate that as amiodarone is used more frequently to manage pediatric arrhythmias, pulmonary fibrosis, a known complication of this antiarrhythmia in adults may be seen with increasing frequency in children.
我们报告了一例婴儿肺纤维化病例,该婴儿因治疗继发于预激综合征的顽固性房室折返性心动过速而接受胺碘酮治疗。9个月时,胸部X线筛查显示一名无症状、发育良好的婴儿出现弥漫性间质浸润。停用胺碘酮后,肺纤维化在6个月内逐渐消退。该病例记录了儿科年龄组中胺碘酮诱发肺纤维化的首例报告。我们推测,随着胺碘酮越来越频繁地用于治疗小儿心律失常,肺纤维化这种成人抗心律失常药物已知的并发症在儿童中可能会更频繁地出现。